Conference Coverage

Hormonal contraception boosts breast cancer risk


 

EXPERT ANALYSIS FROM SDEF HAWAII DERMATOLOGY SEMINAR

Dr. Eichenfield pointed out that among Danish patients who used an oral contraceptive for less than 5 years, the excess risk of breast cancer went away within a year of stopping the medication. If patients used hormonal contraception for more than 5 years, the excess breast cancer risk lasted for 5 years after stopping.

He noted that the antiandrogen spironolactone, widely used off-label to treat adult female acne, has been shown to be free of any increased breast cancer risk.

He reported serving as a consultant to and/or recipient of research grants from more than a dozen pharmaceutical companies.

SDEF/Global Academy for Medical Education and this news organization are owned by the same parent company..

Pages

Recommended Reading

VIDEO: What to monitor during isotretinoin treatment
MDedge Dermatology
Late-breaking research presented at AAD on Saturday February 17
MDedge Dermatology
Acne is linked to higher chances of major depression
MDedge Dermatology
Debunking Acne Myths: Does Wearing Makeup Cause Acne?
MDedge Dermatology
Evaluating Dermatology Apps for Patient Education
MDedge Dermatology
VIDEO: Cannabinoids in dermatology
MDedge Dermatology
Review finds some evidence of efficacy for nonpharmacological acne therapies
MDedge Dermatology
Cost, coverage concerns cited as barriers to acne medication adherence
MDedge Dermatology
Microneedling improved acne scars in small study of patients with darker skin
MDedge Dermatology
Treating female-to-male transgender adolescents with acne presents unique concerns with depression
MDedge Dermatology